A phase I study of mirvetuximab soravtansine (MIRV) and gemcitabine (G) in pts with selected FRα-positive solid tumours: Results in the endometrial cancer (EC) cohort

被引：2
|
作者：
Cristea, M. C. [1 ]
Frankel, P. [2 ]
Synold, T. [3 ]
Stewart, D. B. [1 ]
Wang, E. [1 ]
Jung, A. [4 ]
Wilczynski, S. [5 ]
Tran, M. [5 ]
Konecny, G. E. [6 ]
Eng, M. [7 ]
Kilpatrick, L. [8 ]
Chen, Y-J. [9 ]
Glaser, S. [9 ]
Han, E. [10 ]
Dellinger, T. [10 ]
Hakim, A. [10 ]
Lee, S. [10 ]
Morgan, R. J. [1 ]
Rodriguez, L. [10 ]
Wakabayashi, M. [10 ]
机构：
[1] City Hope Comprehens Canc Ctr, Med Oncol, Duarte, CA USA
[2] City Hope Comprehens Canc Ctr, Dept Computat & Quantitat Med, Duarte, CA USA
[3] City Hope Natl Med Ctr, Canc Biol, Duarte, CA USA
[4] City Hope Comprehens Canc Ctr, Diagnost Radiol, Duarte, CA USA
[5] City Hope Comprehens Canc Ctr, Div Program, Duarte, CA USA
[6] Univ Calif Los Angeles, Dept Med, David Geffen Sch, Los Angeles, CA 90024 USA
[7] City Hope Natl Med Ctr, Div Program, Duarte, CA USA
[8] City Hope Natl Med Ctr, Shared Rsc Clin Trial Off, Duarte, CA USA
[9] City Hope Comprehens Canc Ctr, Radiat Oncol, Duarte, CA USA
[10] City Hope Comprehens Canc Ctr, Surg, Duarte, CA USA
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.1002
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
863P
引用
收藏
页码：S639 / S639
页数：1
相关论文
共 50 条
  • [31] A phase II study of IV gemcitabine (G) and oral capecitabine (C) in patients (pts) with advanced renal cell cancer (RCC): Results of Southwest Oncology Group study 0312
    Van Veldhuizen, P. J.
    Hussey, M.
    Lara, P. N.
    Gumerlock, P. H.
    Clark, J.
    Lange, M. K.
    Crawford, E. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [32] Phase I study of liposomal formulation of eribulin (E7389-LF) in patients (pts) with advanced solid tumours: Primary results of dose-escalation part
    Yamamoto, N.
    Sato, J.
    Koyama, T.
    Iwasa, S.
    Shimomura, A.
    Kondo, S.
    Kitano, S.
    Yonemori, K.
    Fujiwara, Y.
    Tamura, K.
    Suzuki, T.
    Takase, T.
    Nishiwaki, Y.
    Nakai, K.
    Shimizu, T.
    ANNALS OF ONCOLOGY, 2019, 30
  • [33] Phase I study of DKN-01 I an anti-DKK1 antibody, in combination with gemcitabine (G) and cisplatin (C) in patients (pts) with advanced biliary cancer.
    Eads, Jennifer Rachel
    Goyal, Lipika
    Stein, Stacey
    El-Khoueiry, Anthony B.
    Manji, Gulam A.
    Abrams, Thomas Adam
    Landau, Steven B.
    Sirard, Cynthia A.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [34] Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer
    Moreno, Lucas
    Casanova, Michela
    Chisholm, Julia C.
    Berlanga, Pablo
    Chastagner, Pascal B.
    Baruchel, Sylvain
    Amoroso, Loredana
    Gallego Melcon, Soledad
    Gerber, Nicolas U.
    Bisogno, Gianni
    Fagioli, Franca
    Geoerger, Birgit
    Bender, Julia L. Glade
    Aerts, Isabelle
    Bergeron, Christophe
    Hingorani, Pooja
    Elias, Ileana
    Simcock, Mathew
    Ferrara, Stefano
    Le Bruchec, Yvan
    Slepetis, Ruta
    Chen, Nianhang
    Vassal, Gilles
    EUROPEAN JOURNAL OF CANCER, 2018, 100 : 27 - 34
  • [35] FORWARD I: A phase 3 study to evaluate the safety and efficacy of mirvetuximab soravtansine (IMGN853) versus chemotherapy in adults with folate receptor alpha (FRa)-positive, platinum-resistant epithelial ovarian cancer, primary peritoneal cancer, or primary fallopian tube cancer
    Moore, K. N.
    Vergote, I.
    Oaknin, A.
    Colombo, N.
    Banerjee, S.
    Oza, A. M.
    Pautier, P.
    Kelly, C. M.
    Malek, K.
    Birrer, M. J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [36] A phase 1b/2 study of INCB039110+nab-paclitaxel (N) and gemcitabine (G) in patients (pts) with advanced solid tumors and pancreatic cancer (PC).
    Beatty, Gregory Lawrence
    Shanda, Safi
    Beck, J. Thaddeus
    Uppal, Nikhil Premparkash
    Cohen, Steven J.
    Donehower, Ross C.
    Gabayan, A. Eli
    Assad, Albert
    Switzky, Julie C.
    Zhen, Huiling
    Von Hoff, Daniel D.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [37] A phase I dose escalation and pharmacokinetic (PK) study of intravenous (iv) aflibercept (VEGF Trap) plus weekly gemcitabine (Gem) in patients (pts) with advanced solid tumors: preliminary results
    Patnaik, A.
    Pipas, M.
    Rosen, L. S.
    Wood, L.
    Phipps, K.
    Mulay, M.
    Garay, C.
    Korc, M.
    Sarantopoulos, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [38] PHASE I DOSE ESCALATION AND PHARMACOKINETIC (PK) STUDY OF IV AFLIBERCEPT (VEGF TRAP) PLUS WEEKLY GEMCITABINE AND DAILY ERLOTINIB IN PATIENTS (PTS) WITH ADVANCED SOLID TUMORS: PRELIMINARY RESULTS
    Sarantopoulos, J.
    Rosen, L.
    Chap, L.
    Mita, A.
    Papadopoulos, K.
    Mita, M.
    Wood, L.
    Nichols, S.
    Tolcher, A.
    Trembly, J.
    Patnaik, A.
    ANNALS OF ONCOLOGY, 2010, 21 : 57 - 57
  • [39] Intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours: Results from the expansion cohort of a phase I study
    Khayat, David
    Tejpar, Sabine
    Spano, Jean-Philippe
    Verslype, Chris
    Bloch, Joel
    Vandecaveye, Vincent
    Assadourian, Sylvie
    Soussan-Lazard, Karen
    Cartot-Coton, Sylvaine
    Van Cutsem, Eric
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (04) : 790 - 797
  • [40] Results of the phase I-II study of gemcitabine (GEM) in combination with oxaliplatin (OX) in patients (pts) with advanced non-small-cell lung cancer (NSCLC) and ovarian cancer (OC).
    Faivre, S
    Raymond, E
    Lokiec, F
    Monnerat, C
    Vicente-Azevedo, J
    Pautier, P
    Lhommé, C
    Kayitalire, L
    Armand, JP
    Le Chevalier, T
    ANNALS OF ONCOLOGY, 2000, 11 : 141 - 141
12345